雾化吸入药物疗法在COVI D-19治疗中的应用及药学监护

新型冠状病毒肺炎(COVID-19)疫情在全世界蔓延,针对COVID-19的临床诊治与药物治疗研究成为热点。目前,尚没有针对COVID-19的特效药物或疫苗,而多项相关的药物临床试验迅速开展,也引起广泛的关注。截至2020年3月18日,共有8项雾化吸入疗法治疗COVID-19的临床试验在国家临床试验中心注册,涉及7种药物。本文介绍了这7种药物的应用研究进展和雾化吸入药学监护,以加强药品使用的风险管理,减少药品使用的不良事件。

Application and Pharmaceutical Care of Nebulized Inhaled Medication in the Treatment of COVID-19

Corona virus disease 2019 (COVID-19) outbreaks have been spreading around the world, and researches on COVID-19 have quickly become the hot topic. There is no specific drug or vaccine against COVID-19 so far. A number of related drug clinical trials have been carried out rapidly and have attracted much attention. Until Mar. 18th, 2020, a total of 8 clinical trials of aerosol inhalation therapy for COVID-19 have been registered in National Clinical Trial Center, involving seven drugs. This article describes the application research of these drugs and pharmaceutical care of aerosol inhalation therapy, to strenghthen the risk management of drug use and reduce the adverse events of drug use.